Intelligent Bio Solutions (INBS) investor relations material

Product innovation and technology

• Introduced a non-invasive, real-time drug testing device using fingertip sweat, offering a pain-free alternative to urine and saliva tests.

• The device collects sweat samples from all ten fingertips in under a minute and delivers results within 10 minutes.

• Features the industry's shortest detection window (12–24 hours), targeting recent drug use and impairment rather than historical consumption.

• Currently stores up to 200 results locally, with future plans for wireless connectivity and a software ecosystem post-FDA approval.

• Device is protected by multiple patents covering both the cartridge and reader technology.

Market opportunity and business model

• U.S. drug testing market is nearing $4 billion and growing, driven by workplace safety and increased drug legalization.

• Main customer base includes construction, transportation, engineering, and manufacturing sectors, with expansion into government and law enforcement trials internationally.

• Razor-blade business model: device costs ~$2,000, each test cartridge ~$20, with recurring revenue from cartridge sales.

• Over 480 active recurring customers, with nearly 500 active accounts globally.

• Manufacturing recently shifted from the UK to Asia, reducing costs and improving margins toward 60–70%.

Regulatory and operational updates

• Product is commercially available internationally but not yet in the U.S. outside forensic markets due to FDA requirements.

• FDA 510(k) submission planned by September, with most clinical trials completed and final trials concluding this month.

• Device calibration is recommended after every 20 tests, with a one-year warranty and a low return rate of 3–4%.

• No current wireless or cloud connectivity to avoid regulatory complications; results can be downloaded via USB.

• Customers confirm positive results with lab-based tests for legal or disciplinary actions.